(820) Cholbam
Drug
Retrophin, Inc.
Total Payments
$1.0M
Transactions
10,310
Doctors
2,786
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $276,490 | 2,773 | 727 |
| 2019 | $128,439 | 4,020 | 1,534 |
| 2018 | $438,286 | 1,898 | 970 |
| 2017 | $178,906 | 1,619 | 678 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $402,785 | 125 | 39.4% |
| Consulting Fee | $286,044 | 271 | 28.0% |
| Grant | $216,000 | 2 | 21.1% |
| Education | $82,114 | 8,746 | 8.0% |
| Food and Beverage | $21,070 | 1,127 | 2.1% |
| Travel and Lodging | $8,096 | 27 | 0.8% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $6,013 | 12 | 0.6% |
Payments by Type
General
$619,336
10,185 transactions
Research
$402,785
125 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| The Replace Registry | Retrophin, Inc. | $160,792 | 0 |
| The Replace Registry | Travere Therapeutics, Inc. | $141,973 | 0 |
| Study of Cholic Acid Capsules | Retrophin, Inc. | $52,524 | 0 |
| An Open Label, Single Center, Nonrandomized Continuation Study of Cholic Acid Capsules in Subjects with Inborn Erros of Bile Acid Synthesis | Retrophin, Inc. | $26,262 | 1 |
Top Doctors Receiving Payments for (820) Cholbam
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Nada Yazigi | — | Washington, DC | $709,364 | 142 |
| James Heubi | — | Cincinnati, OH | $95,789 | 81 |
| , MD | Pediatrics | Dallas, TX | $25,503 | 43 |
| , M.D | Medical Biochemical Genetics | Palo Alto, CA | $22,763 | 29 |
| , M.D | Pediatrics | Houston, TX | $21,897 | 43 |
| , M.D | Pediatric Gastroenterology | Birmingham, AL | $19,255 | 36 |
| , M.D | Pediatrics | Atlanta, GA | $15,700 | 25 |
| , M.D | Clinical Genetics (M.D.) | Topeka, IN | $13,199 | 32 |
| , MD | Pediatrics | Portland, OR | $8,300 | 18 |
| , MD | Pediatric Gastroenterology | Miami, FL | $7,593 | 32 |
| , MD, PHD | Pediatric Gastroenterology | Atlanta, GA | $5,574 | 3 |
| , M.D | Pediatrics | San Francisco, CA | $5,147 | 4 |
| , M.D | Pediatric Gastroenterology | Philadelphia, PA | $3,000 | 1 |
| , M.D | Pediatrics | New York, NY | $2,198 | 4 |
| , MD | Pediatrics | Pittsburgh, PA | $1,757 | 6 |
| , MD | Clinical Genetics (M.D.) | Miami, FL | $1,694 | 4 |
| , MD | Pediatric Gastroenterology | Wilmington, DE | $1,626 | 4 |
| , M.D., PH.D | Pediatric Gastroenterology | Cincinnati, OH | $1,622 | 2 |
| , M.D | Neurology | San Francisco, CA | $1,622 | 2 |
| , MD | Ophthalmology | Iowa City, IA | $1,601 | 2 |
| , MD | Pediatric Transplant Hepatology | Milwaukee, WI | $1,507 | 2 |
| , MD | Clinical Genetics (M.D.) | Omaha, NE | $1,503 | 4 |
| , M.D | Pediatrics | Bronx, NY | $395.75 | 18 |
| , M.D | Nephrology | Columbus, OH | $375.00 | 3 |
| Patrick Mckiernan | Pediatric Gastroenterology | Pittsburgh, PA | $351.68 | 8 |
Ad
Manufacturing Companies
- Retrophin, Inc. $745,631
- Travere Therapeutics, Inc. $276,490
Product Information
- Type Drug
- Total Payments $1.0M
- Total Doctors 2,786
- Transactions 10,310
About (820) Cholbam
(820) Cholbam is a drug associated with $1.0M in payments to 2,786 healthcare providers, recorded across 10,310 transactions in the CMS Open Payments database. The primary manufacturer is Retrophin, Inc..
Payment data is available from 2017 to 2020. In 2020, $276,490 was paid across 2,773 transactions to 727 doctors.
The most common payment nature for (820) Cholbam is "Unspecified" ($402,785, 39.4% of total).
(820) Cholbam is associated with 4 research studies, including "The Replace Registry" ($160,792).